跳至主要内容
临床试验/ISRCTN58905233
ISRCTN58905233已完成未知

Apolipoprotein B and low density lipoprotein size in type two diabetes: effect of atorvastatin and gemfibrozil

Hospital Sant Pau (Spain)0 个研究点目标入组 44 人开始时间: 2007年4月24日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
44

研究概览

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Men and women with type two diabetes, aged 35 to 75 years
  • 2. No treatment known to interfere with lipid metabolism (nonselective B-blockers, high dose diuretics, systemic steroids, lipid-lowering drugs) in the month preceding inclusion in the study
  • 3. Plasma Low Density Lipoprotein cholesterol (LDLc) greater than 100 mg/dl (2.6 mmol/litre), and triglycerides less than 400 mg/dl (4.51mmol/litre)

排除标准

  • 1. Pregnant
  • 2. No reliable contraceptive method was used
  • 3. Serum creatinine more than 1.7 mg/dl (150 umol/litre)
  • 4. Hepatic dysfunction (transaminases greater than 1.5 times upper normal limit at inclusion)
  • 5. Creatine kinase more than three times the upper normal limit
  • 6. Acute or chronic disorders that might interfere with compliance

研究者

发起方
Hospital Sant Pau (Spain)

相似试验